Want to see HK:2197 full AI Analyst Report?
2197 Stock Chart & Stats
HK$2.37
>-HK$0.01(-2.10%)
At close: 4:00 PM EST
HK$2.37
>-HK$0.01(-2.10%)
Day’s Range― - ―
52-Week RangeHK$1.32 - HK$3.20
Previous CloseN/A
Volume1.38M
Average Volume (3M)4.22M
Market Cap
HK$2.75B
Enterprise ValueHK$1.97K
Total Cash (Recent Filing)HK$104.77M
Total Debt (Recent Filing)HK$2.08M
Price to Earnings (P/E)2.7
Beta2.48
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding1,298,600,700
10 Day Avg. Volume4,700,105
30 Day Avg. Volume4,223,622
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-1.47
Price to Sales (P/S)775.86
P/FCF Ratio-13.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vaccine And Biologics FocusA focused position in vaccines and biologics gives Clover a clearly defined healthcare mission spanning research, development, manufacturing, and commercialization. This integrated scope can support product continuity and preserve strategic relevance as the company advances immunology-focused programs.
Protein Engineering CapabilitiesProtein engineering and adjuvant technologies provide a specialized technical foundation for creating immunology products. These capabilities can support differentiated vaccine development and give the company reusable scientific expertise across programs, rather than relying on a single commercial product.
Multiple Monetization ChannelsClover has more than one potential monetization route, combining vaccine product sales with collaboration, licensing, milestone, royalty, and possible grant income. A broader revenue model can create additional paths to fund development and commercial expansion over time.
Bears Say
Revenue CollapseThe sharp 2025 revenue decline indicates that Clover’s commercial performance remains highly unstable and vulnerable to changes in vaccine demand, procurement, or product availability. Such a contraction reduces operating scale and makes sustained investment in development more difficult.
Negative Shareholder EquityPersistent negative equity reflects accumulated losses and materially limits financial flexibility. It can make balance-sheet leverage harder to assess, increase sensitivity to refinancing or additional funding, and constrain Clover’s ability to absorb setbacks while continuing investment in its pipeline.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the business has not yet generated self-sustaining cash from operations. Continued burn increases reliance on external funding or asset reductions, potentially limiting strategic choices and creating dilution or continuity risk.
Clover Biopharmaceuticals Ltd. News
2197 FAQ
What was Clover Biopharmaceuticals Ltd.’s price range in the past 12 months?
Clover Biopharmaceuticals Ltd. lowest stock price was HK$1.32 and its highest was HK$3.20 in the past 12 months.
What is Clover Biopharmaceuticals Ltd.’s market cap?
Clover Biopharmaceuticals Ltd.’s market cap is HK$2.75B.
When is Clover Biopharmaceuticals Ltd.’s upcoming earnings report date?
Clover Biopharmaceuticals Ltd.’s upcoming earnings report date is Mar 30, 2027 which is in 190 days.
How were Clover Biopharmaceuticals Ltd.’s earnings last quarter?
Clover Biopharmaceuticals Ltd. released its earnings results on Aug 25, 2026. The company reported HK$0.86 earnings per share for the quarter.
Is Clover Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clover Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Clover Biopharmaceuticals Ltd. pay dividends?
Clover Biopharmaceuticals Ltd. does not currently pay dividends.
What is Clover Biopharmaceuticals Ltd.’s EPS estimate?
Clover Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Biopharmaceuticals Ltd. have?
Clover Biopharmaceuticals Ltd. has 1,298,600,700 shares outstanding.
What happened to Clover Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Clover Biopharmaceuticals Ltd. reported an EPS of HK$0.86 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Clover Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:2197
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Biopharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-57.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Technical Analysis
Brii Biosciences Limited
―
Genor Biopharma Holdings Limited
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
AIM Vaccine Co., Ltd. Class H
―